Century Casinos Sees 'Green Shoots Across Several Areas Within Its Business,' Says Bullish Analyst
Century Casinos, Inc. CNTY shares continued an upward trajectory Tuesday, after climbing around 65% over the past month.
Century Casinos, Inc. (CNTY) Q3 2024 Earnings Call Transcript
Century Casinos, Inc. (NASDAQ:CNTY ) Q3 2024 Earnings Conference Call November 4, 2024 10:00 AM ET Company Participants Peter Hoetzinger - Co-Chief Executive Officer & President Erwin Haitzmann - Co-Chief Executive Officer Conference Call Participants Jordan Bender - Citizens JMP Jeffrey Stantial - Stifel Financial Corp. Chad Beynon - Macquarie Operator Good day everyone and welcome to today's Century Casinos Q3 2024 Earnings Call. At this time, all participants are in a listen-only mode.
Century Casinos (CNTY) Reports Q3 Loss, Lags Revenue Estimates
Century Casinos (CNTY) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.47 per share a year ago.
Century Casinos, Inc. (CNTY) Q2 2024 Earnings Call Transcript
Century Casinos, Inc. (NASDAQ:CNTY ) Q2 2024 Earnings Conference Call August 8, 2024 10:00 AM ET Company Participants Peter Hoetzinger - Co-CEO & President Erwin Haitzmann - Co-CEO Conference Call Participants Jeffrey Stantial – Stifel Financial Corp. Chad Beynon - Macquarie Jordan Bender - Citizens JMP Operator Good day, everyone, and welcome to the Century Casinos Q2 2024 Earnings Call. [Operator Instructions] Please note this meeting is being recorded.
Century Casinos (CNTY) Reports Q2 Loss, Lags Revenue Estimates
Century Casinos (CNTY) came out with a quarterly loss of $1.36 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.06 per share a year ago.
3 Budget-Friendly Stocks With Millionaire-Making Potential
Investors with a high tolerance for risk looking for huge returns often find budget-friendly stocks to be a great option. While low-valued stocks often have a bad reputation due to their accompanying risk, it's important to find some gems with enough research.
Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101
Positive poster presentation results were released at ASCO 2024 from the phase 1 ELiPSE-1 study, which used CNTY-101 for the treatment of patients with relapsed/refractory CD19-positive non-Hodgkin lymphoma patients. The global non-Hodgkin Lymphoma market is expected to surge to $11 billion by 2029. Initiation of phase 1 CALiPSO-1 study, using CNTY-101 for patients with systemic lupus erythematosus, is expected in the 1st half of 2024; Data from this study is to be released 2nd half of 2024.
